A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

Study ID
NCT01509911

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients

More informations

Trial Starting Date

Jan 31,2012

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit